Institut de Cancerologie de la Loire

Saint-Priest-en-Jarez, Pays de la Loire Region 42271

0 studies enrolling now · 2 studies all time

What they study most

Carcinoma, Renal Cell, HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer

Studies at this site

• A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05) — Running, not enrolling
• A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC) — Completed